426 related articles for article (PubMed ID: 27372054)
21. Mechanism suppressing H3K9 trimethylation in pluripotent stem cells and its demise by polyQ-expanded huntingtin mutations.
Irmak D; Fatima A; Gutiérrez-Garcia R; Rinschen MM; Wagle P; Altmüller J; Arrigoni L; Hummel B; Klein C; Frese CK; Sawarkar R; Rada-Iglesias A; Vilchez D
Hum Mol Genet; 2018 Dec; 27(23):4117-4134. PubMed ID: 30452683
[TBL] [Abstract][Full Text] [Related]
22. Human Huntington's disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species.
O'Regan GC; Farag SH; Casey CS; Wood-Kaczmar A; Pocock JM; Tabrizi SJ; Andre R
J Neuroinflammation; 2021 Apr; 18(1):94. PubMed ID: 33874957
[TBL] [Abstract][Full Text] [Related]
23. Induced neural stem cells as a means of treatment in Huntington's disease.
Choi KA; Hong S
Expert Opin Biol Ther; 2017 Nov; 17(11):1333-1343. PubMed ID: 28792249
[TBL] [Abstract][Full Text] [Related]
24. Human Huntington's Disease iPSC-Derived Cortical Neurons Display Altered Transcriptomics, Morphology, and Maturation.
Mehta SR; Tom CM; Wang Y; Bresee C; Rushton D; Mathkar PP; Tang J; Mattis VB
Cell Rep; 2018 Oct; 25(4):1081-1096.e6. PubMed ID: 30355486
[TBL] [Abstract][Full Text] [Related]
25. Stem cell therapy and cellular engineering for treatment of neuronal dysfunction in Huntington's disease.
Choi KA; Hwang I; Park HS; Oh SI; Kang S; Hong S
Biotechnol J; 2014 Jul; 9(7):882-94. PubMed ID: 24827816
[TBL] [Abstract][Full Text] [Related]
26. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells.
Jeon I; Lee N; Li JY; Park IH; Park KS; Moon J; Shim SH; Choi C; Chang DJ; Kwon J; Oh SH; Shin DA; Kim HS; Do JT; Lee DR; Kim M; Kang KS; Daley GQ; Brundin P; Song J
Stem Cells; 2012 Sep; 30(9):2054-62. PubMed ID: 22628015
[TBL] [Abstract][Full Text] [Related]
27. iPSC-based drug screening for Huntington's disease.
Zhang N; Bailus BJ; Ring KL; Ellerby LM
Brain Res; 2016 May; 1638(Pt A):42-56. PubMed ID: 26428226
[TBL] [Abstract][Full Text] [Related]
28. Concise Review: The Use of Stem Cells for Understanding and Treating Huntington's Disease.
Connor B
Stem Cells; 2018 Feb; 36(2):146-160. PubMed ID: 29178352
[TBL] [Abstract][Full Text] [Related]
29. Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery.
Kunkanjanawan T; Carter R; Ahn KS; Yang J; Parnpai R; Chan AWS
SLAS Discov; 2017 Jul; 22(6):696-705. PubMed ID: 28027448
[TBL] [Abstract][Full Text] [Related]
30. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
Lu B; Palacino J
FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
[TBL] [Abstract][Full Text] [Related]
31. Genomic Analysis Reveals Disruption of Striatal Neuronal Development and Therapeutic Targets in Human Huntington's Disease Neural Stem Cells.
Ring KL; An MC; Zhang N; O'Brien RN; Ramos EM; Gao F; Atwood R; Bailus BJ; Melov S; Mooney SD; Coppola G; Ellerby LM
Stem Cell Reports; 2015 Dec; 5(6):1023-1038. PubMed ID: 26651603
[TBL] [Abstract][Full Text] [Related]
32. Modeling Huntington's disease with induced pluripotent stem cells.
Kaye JA; Finkbeiner S
Mol Cell Neurosci; 2013 Sep; 56():50-64. PubMed ID: 23459227
[TBL] [Abstract][Full Text] [Related]
33. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.
HD iPSC Consortium
Cell Stem Cell; 2012 Aug; 11(2):264-78. PubMed ID: 22748968
[TBL] [Abstract][Full Text] [Related]
34. Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.
Alpaugh M; Masnata M; de Rus Jacquet A; Lepinay E; Denis HL; Saint-Pierre M; Davies P; Planel E; Cicchetti F
Mol Ther; 2022 Apr; 30(4):1500-1522. PubMed ID: 35051614
[TBL] [Abstract][Full Text] [Related]
35. Chromatin accessibility and transcription dynamics during in vitro astrocyte differentiation of Huntington's Disease Monkey pluripotent stem cells.
Goodnight AV; Kremsky I; Khampang S; Jung YH; Billingsley JM; Bosinger SE; Corces VG; Chan AWS
Epigenetics Chromatin; 2019 Nov; 12(1):67. PubMed ID: 31722751
[TBL] [Abstract][Full Text] [Related]
36. Use of human stem cells in Huntington disease modeling and translational research.
Golas MM; Sander B
Exp Neurol; 2016 Apr; 278():76-90. PubMed ID: 26826449
[TBL] [Abstract][Full Text] [Related]
37. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons.
Nekrasov ED; Vigont VA; Klyushnikov SA; Lebedeva OS; Vassina EM; Bogomazova AN; Chestkov IV; Semashko TA; Kiseleva E; Suldina LA; Bobrovsky PA; Zimina OA; Ryazantseva MA; Skopin AY; Illarioshkin SN; Kaznacheyeva EV; Lagarkova MA; Kiselev SL
Mol Neurodegener; 2016 Apr; 11():27. PubMed ID: 27080129
[TBL] [Abstract][Full Text] [Related]
38. Generation of induced pluripotent stem cell line, ICGi033-A, by reprogramming peripheral blood mononuclear cells from a patient with Huntington's disease.
Grigor'eva EV; Malakhova AA; Sorogina DA; Pavlova SV; Malankhanova TB; Abramycheva NY; Klyushnikov SA; Illarioshkin SN; Zakian SM
Stem Cell Res; 2022 Aug; 63():102868. PubMed ID: 35872525
[TBL] [Abstract][Full Text] [Related]
39. Modeling Huntington׳s disease with patient-derived neurons.
Mattis VB; Svendsen CN
Brain Res; 2017 Feb; 1656():76-87. PubMed ID: 26459990
[TBL] [Abstract][Full Text] [Related]
40. The ubiquitin ligase UBR5 suppresses proteostasis collapse in pluripotent stem cells from Huntington's disease patients.
Koyuncu S; Saez I; Lee HJ; Gutierrez-Garcia R; Pokrzywa W; Fatima A; Hoppe T; Vilchez D
Nat Commun; 2018 Jul; 9(1):2886. PubMed ID: 30038412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
